Boston Scientific (NYSE:BSX) Director Acquires $50,088.94 in Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger purchased 1,042 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $48.07 per share, with a total value of $50,088.94. Following the completion of the transaction, the director owned 14,920 shares of the company’s stock, valued at approximately $717,204.40. The trade was a 7.51% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Boston Scientific Stock Performance

NYSE:BSX opened at $49.35 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.22 and a current ratio of 1.24. The stock has a market capitalization of $71.53 billion, a P/E ratio of 19.98, a PEG ratio of 1.08 and a beta of 0.56. The company has a 50 day moving average price of $45.75 and a 200 day moving average price of $60.73. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the company earned $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Boston Scientific

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Group LLC acquired a new position in Boston Scientific during the 4th quarter worth approximately $28,064,000. Meiji Yasuda America Inc acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $4,708,000. Harvest Portfolios Group Inc. lifted its holdings in shares of Boston Scientific by 6.1% in the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after buying an additional 34,598 shares during the period. LBP AM SA boosted its stake in shares of Boston Scientific by 8.4% in the fourth quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock valued at $41,419,000 after buying an additional 33,534 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $4,914,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on BSX shares. Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Needham & Company LLC decreased their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. Citigroup dropped their price target on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.